Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07363148Recruiting
Study of MB-1 for weight and metabolic health in overweight adults
This study tests a new supplement called MB-1 to see if it can improve metabolic health in adults who are overweight or obese. If you are between 18 and 50, have a certain waist size, and have been at a stable weight for the last 3 months, you may qualify.
London, OntarioAges 18–50 - NCT07369492RecruitingPhase 1
Study of BAFF-R CAR-T cells for CD19-negative B-cell lymphoma
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
SuzhouAges 18 years+ - NCT07367529RecruitingPhase 1/Phase 2
TQB6411 for injection for lung cancer
This trial tests a new drug called TQB6411 for people with lung cancer that can be measured by scans. The drug is given by injection, and the study will see if it is safe and if it helps shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07370740Recruiting
Bloat relief study for healthy women with frequent bloating
This trial tests a supplement called 'Bloat' to see if it reduces post-meal bloating in healthy women who often feel bloated. If you're a woman aged 18–65 with regular bloating, this study might help find a gentle solution.
London, OntarioAges 18–65 - NCT07368270RecruitingPhase 1
Anti-PD1 armored CAR-T cells for adults with relapsed/refractory DLBCL
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
SuzhouAges 18 years+ - NCT07363460RecruitingPhase 2
HSK39297 tablets for active lupus nephritis
This study tests a new drug called HSK39297 combined with standard treatments (steroids and mycophenolate mofetil) for people with active lupus nephritis. It aims to see if the combination is safe and effective in reducing kidney inflammation.
Nanjing, JiangsuAges 18–75 - NCT07365319RecruitingPhase 2/Phase 3
New drug combo for stage 4 lung cancer
This trial tests a new drug called EIK1001 combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who have not been treated before. The goal is to see if adding EIK1001 helps shrink tumors more than the current standard treatment.
Daphne, AlabamaAges 18 years+ - NCT07362355RecruitingPhase 2
New gout pill combined with febuxostat for high uric acid
This trial tests an experimental tablet (SHR4640) added to the standard gout medicine febuxostat (40 mg daily) for people whose uric acid remains too high despite febuxostat alone. The goal is to see if the combination lowers uric acid more effectively and safely.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07362017RecruitingPhase 3
Ponesimod for moderate to severe plaque psoriasis
This trial tests an investigational drug called ponesimod for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at improving skin symptoms.
Glendale, ArizonaAges 18–65 - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT06836505RecruitingPhase 1/Phase 2
CAR-T cell therapy for relapsed neuroblastoma and related tumors
This trial tests a new immune cell therapy (CAR-T) for people whose neuroblastoma or desmoplastic small round cell tumor has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can help shrink or control the cancer.
Guangzhou, GuangdongAges 1–50 - NCT06021678RecruitingPhase 1/Phase 2
EX103 for relapsed or refractory CD20-positive lymphoma
This trial tests a new drug called EX103 for people whose non-Hodgkin lymphoma (a cancer of the immune system) has come back or not responded to earlier treatments. The goal is to see if EX103 is safe and can shrink tumors.
Zhengzhou, HenanAges 18 years+ - NCT06173219RecruitingPhase 1/Phase 2
Radiation and immunotherapy for advanced cancer
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07357285Recruiting
Stroke treatment trial for smaller vessel blockages
This trial tests a new catheter device to remove blood clots from smaller brain arteries in people having a stroke. It aims to see if the device is safe and effective for patients treated within 24 hours of symptoms starting.
BonnAges 18 years+ - NCT07356531Recruiting
Thermosensitive Embolic Agent for Liver Cancer TACE
This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.
Hefei, AnhuiAges 18–80 - NCT07355062RecruitingPhase 3
Testing Veverimer for metabolic acidosis in kidney disease
This study tests an oral medicine called Veverimer to see if it safely corrects low bicarbonate levels (metabolic acidosis) in people with chronic kidney disease. It might help you feel better and protect your kidneys.
Chula Vista, CaliforniaAges 18 years+ - NCT07355075RecruitingPhase 2/Phase 3
Study of a new cream for moderate to severe eczema
This study tests an investigational cream for moderate to severe eczema. It helps see if the cream reduces symptoms like itching and skin inflammation.
Irving, TexasAges 18–80 - NCT07353931RecruitingPhase 3
Study of eloralintide for knee osteoarthritis pain in people with overweight or obesity
This trial tests an investigational drug called eloralintide to see if it can reduce knee pain in people with osteoarthritis who also have overweight or obesity. You may be able to join if you have knee osteoarthritis, a BMI of 27 or higher, and have tried to lose weight with diet before.
Mobile, AlabamaAges 18 years+ - NCT07360808Recruiting
Fat Cell Therapy for Hand Problems in Scleroderma
This study tests whether a person's own fat cells (processed into regenerative cells) can be injected into the hands to improve hand function and reduce skin thickening in systemic sclerosis (scleroderma). It’s designed for people whose hand problems are significant but not too severe.
Guangzhou, GuangdongAges 18–70 - NCT07354009Recruiting
Stent implant for lowering eye pressure in open-angle glaucoma
This trial tests a small stent to help drain fluid from the eye and lower pressure in people who have both open-angle glaucoma and cataracts. The stent is placed during routine cataract surgery.
HangzhouAges 18–90 - NCT07358182Recruiting
Trastuzumab-rezetecan for breast cancer with HER2 protein
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT07357584RecruitingPhase 4
Quick-start HIV treatment with doravirine for newly diagnosed adults
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18–90 - NCT07357038Recruiting
AmBisome for fungal infections in children with blood cancer
This study follows children and teens with blood cancers who got a fungal infection while on preventive antifungal medicine. It looks at how well liposomal amphotericin B (AmBisome) works and how safe it is for them.
Tianjin, Tianjin MunicipalityAges 1 month–18 years
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.